Meeting
2015 ASCO Annual Meeting
Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.
Authors
Daniel A. Goldstein
Winship Cancer Institute of Emory University, Atlanta, GA
Daniel A. Goldstein , Bilal B. Ahmad , Qiushi Chen , Turgay Ayer , David H. Howard , Joseph Lipscomb , Bassel F. El-Rayes , Christopher Flowers
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality of Care
Track
Health Services Research and Quality of Care
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 33, 2015 (suppl; abstr 6613)
DOI
10.1200/jco.2015.33.15_suppl.6613
Abstract #
6613
Poster Bd #
170
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.
First Author: Daniel A. Goldstein
Poster
2023 ASCO Annual Meeting
Cost-effectiveness analysis of later-line therapies for metastatic colorectal cancer (mCRC) based on a novel methodology of network meta-analysis (NMA) of survival curves.
First Author: Mavis Obeng-Kusi
Poster
2019 Gastrointestinal Cancers Symposium
Validation of cost-effectiveness of trifluridine/tipiracil versus best supportive care and regorafenib for previously treated metastatic colorectal cancer in the UK using phase IIIb PRECONNECT early access clinical trial data in the real world setting.
First Author: Javier Sabater
Poster
2017 Gastrointestinal Cancers Symposium
Cost effectiveness of maintenance bevacizumab in patients with metastatic colorectal cancer.
First Author: Joel Lange